Skip to content
Scb logo white
Scb logo color
  • Home
  • About
  • Platform
  • Pipeline
  • Collaborations
  • News
  • Careers
  • Contact

Latest news and developments

Screenshot 2025 09 09 at 10.50.22 News Release
News Release

Scenic Biotech Appoints Dr. Roland W. Bürli as CSO to Advance Pipeline of Modifier Therapies in Neuro- and Metabolic Diseases

Rene van den oever News Release
News Release

Scenic Biotech Publishes Novel Drug Target for Mitochondrial and Cardiac Disease in Nature

Scb about 2024 News Release
News Release

Scenic Enters License and Research Agreement with Alnylam

Werksituatie scenic biotech 05 Announcement
Announcement

Scenic Biotech Extends Research Collaboration with Bristol Myers Squibb

Drug target review@4x Coverage
Coverage

Scenic Biotech and Stanford University Collaboration Featured in Drug Target Review

Pexels pixabay 256262 News Release
News Release

Scenic Biotech Announces Nature Publication on the Discovery of Drug Target PLA2G15, a Modifier in Lysosomal Disease

Alexander vos 1x News Release
News Release

Alexander Vos Appointed Chairman of Scenic Biotech’s Board of Directors

Ben machielse News Release
News Release

Scenic Biotech Appoints Industry Veteran Ben Machielse to Board of Directors

Platform 1@3x News Release
News Release

Scenic Biotech enters into Research Collaboration with Bristol Myers Squibb

About 1@3x News Release
News Release

Scenic Biotech Announces Positive Preclinical Data for its QPCTL Inhibitor SC-2882

Drug target review@4x Coverage
Coverage

Scenic’s Vincent Blomen in Drug Target Review

News 1@3x News Release
News Release

Scenic Biotech Enters Cooperative Research and Development Agreement with the National Institutes of Health for Genetic Modifier-Based Treatment Approach for Niemann-Pick Type C Disease

HOME ABOUT PLATFORM PIPELINE COLLABORATIONS NEWS CAREERS CONTACT

© Scenic Biotech 2025

Privacy Policy Disclaimer Cookies

Webdesign by Marsmedia


Linkedin icon

Manage Consent
We use cookies to optimize our website and our service.
Functional cookies Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}